Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05967689
Title A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation. (REZILIENT2)
Acronym REZILIENT2
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Taiho Oncology, Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | TUR | ITA | GBR | FRA | ESP | DEU | CAN | AUS


No variant requirements are available.